DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1195460
Title:
Cotargeting the Trinity of DNA Damage Repair Sensing Kinases in Prostate Cancer
Report Date:
2022-10-01
Abstract:
In this grant, we will systematically establish the preclinical utility of Compound B for clinical translation as combination therapy with cytotoxic therapies. Specifically, we will Specific Aim 1: Characterize effects of RUVBL1/2 inhibition on DNA damage repair and induction of apoptosis in prostate cancer cells in vitro and patient derived explants ex vivo Specific Aim 2: Evaluate the therapeutic efficacy of combining RUVBL1/2 inhibition with ionizing radiation on DNA damage repair and cell survival of prostate cancer xenografts in vivo Specific Aim 3: Characterize immunostimulatory effects of RUVBL1/2 inhibition in prostate cancer cells in vitro, ex vivo and in vivo using immuncompetent syngeneic tumor models. We expect that our data will establish the preclinical rationale for developing clinical trials with RUVBL1/2 inhibitors in prostate cancer.
Document Type:
Conference:
Journal:
Pages:
9
File Size:
1.04MB
W81XWH-21-1-0687, PC200687
(W81XWH2110687, PC200687);
Contracts:
Grants:
Distribution Statement:
Approved For Public Release
